According to a Reuters report issued late last night, the U.S. Food and Drug Administration (FDA) has rejected an application by Amgen to market denosumab (Xgeva?) as a treatment to delay the onset of bone metastases in men with non-metastatic, castration-resistant prostate cancer (nmCRPC).
This will not come as a surprise to most regular readers of this blog. The FDA?s advisory committee had?already voted against approval of denosumab for this indication.
A media release issued by Amgen states that:
The FDA determined that the effect on bone metastases-free survival (BMFS) was of insufficient magnitude to outweigh the risks (including osteonecrosis of the jaw) of XGEVA in the intended population, and requested data from an adequate and well-controlled trial(s) demonstrating a favorable risk-benefit profile for XGEVA that is generalizable to the U.S. population.
Whether Amgen will consider further clinical trials in an attempt to gain approval of denosumab for prevention of progression of prostate cancer in men with nmCRPC is an unanswered question at this time. The FDA?s most recent decision has no effect on the currently approved use of denosumab for the prevention of fractures and other skeletal-related events in?men with metastatic prostate cancer.
Like this:
Be the first to like this post.
Filed under: Management, Treatment Tagged: | castration-resistant, CRPC, denosumab, non-metastatic
while you were sleeping happy halloween happy halloween history of halloween
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন